Tag: Vamorolone

Approved by the FDA in 2023 for Duchenne muscular dystrophy, vamorolone represents a new class of corticosteroids with a modified mechanism of action. This innovation prompts the critical question: what is the steroid equivalent of vamorolone, and how does it fundamentally differ from traditional steroids like prednisone?

In October 2023, the U.S. Food and Drug Administration (FDA) approved vamorolone (brand name Agamree) for the treatment of Duchenne muscular dystrophy (DMD), signaling a new approach in steroid therapy. This first-in-class drug is a novel dissociative corticosteroid, designed to retain the therapeutic benefits of traditional steroids while minimizing common adverse side effects.